Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue

References

• Ren H, Zhao H, Wang T, et al. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura. Clin Immunol 2006;120:205‐11
   PubMed Web of Science ®Google Scholar
• Andersson P-O, Wadenvik H. Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy. Exp Rev Mol Med 2004;6:1‐17
   PubMedGoogle Scholar
• Ramadan K, El-Agnaf M. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. Clin Lab Haematol 2005;27:267‐9
   PubMedGoogle Scholar
• Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr 2005;94:178‐84
   PubMed Web of Science ®Google Scholar
• Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. British Journal of Haematology 2002;118:933‐44
   PubMed Web of Science ®Google Scholar
• Cines D, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Ann Rev Med 2005;56:425‐42
   PubMed Web of Science ®Google Scholar
• Neylon A, Saunders P, Howard M, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966‐74
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909‐13
   PubMed Web of Science ®Google Scholar
• Cines D, Blanchette V. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995‐1008
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386‐93
   PubMed Web of Science ®Google Scholar
• Bottiger L, Westerholm B. Thrombocytopenia. I. Incidence and aetiology. Acta Med Scand 1972;191:535‐40
   PubMed Web of Science ®Google Scholar
• Cohen Y, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630‐8
   PubMed Web of Science ®Google Scholar
• Portielje J, Westendorp R, Kluin-Nelemans H, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549‐54
   PubMed Web of Science ®Google Scholar
• Arnold D, Dentali F, Crowther M, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25‐33
   PubMed Web of Science ®Google Scholar
• Bussel J, Kuter D, George J, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672‐81
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Procedure for common drug review. July 2009, i-51. 2009. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health (CADTH)
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd edn. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health (CADTH), 2006
   Google Scholar
• McMillan R, Bussel J, George J, et al. Self-reported health‐related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008;83:150‐4
   PubMed Web of Science ®Google Scholar
• Mathias S, Gao S, Miller K, et al. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 2008;6:13
   PubMed Web of Science ®Google Scholar
• Barnard D, Woloski M, Feeny D, et al. Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents. J Pediatr Hematol Oncol 2003;25:56‐62
   PubMed Web of Science ®Google Scholar
• Mathias S, Bussel J, George J, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007;5:11
   PubMed Web of Science ®Google Scholar
• Mathias S, Bussel J, George J, et al. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Therapeut 2007;29:950‐62
   PubMed Web of Science ®Google Scholar
• George J, Mathias S, Go R, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2008;144:409‐15
   PubMed Web of Science ®Google Scholar
• O'Brien S, Ritchey A, Smith K. A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer 2007;48:173‐80
   PubMed Web of Science ®Google Scholar
• Kunz K, Kuppermann M, Bowe T, et al. Protein A immunoadsorption column versus splenectomy in the treatment of steroid-resistant immune thrombocytopenic purpura. A cost-effectiveness analysis. Int J Technol Assess Health Care 1996;12:436‐49
   PubMed Web of Science ®Google Scholar
• Sackett D, Torrance G. The utility of different health states as perceived by the general public. J Chronic Dis 1978;31:697‐704
   PubMedGoogle Scholar
• Gold MR, Patrick DL, Torrance GW, eds. Identifying and valuing outcomes. In: Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996. p 82-123
   Google Scholar
• Froberg D, Kane R. Methodology for measuring health-state preferences–II: scalling methods. J Clin Epidemiol 1989;42:459‐71
   PubMed Web of Science ®Google Scholar
• Torrance G. Utility Approach to measuring health-related quality of life. J Chronic Dis 1987;40:593‐600
   PubMedGoogle Scholar
• Gafni A. Encyclopedia of biostatistics - “The Time Trade-Off Technique”. In: Armitage P, Colton T, eds. Baffins Lane, UK: John Wiley and Sons Ltd, 1998. p 4528-32
   Google Scholar
• Sun J. Adjusting distributions of the Health Utilities Index Mark 3 utility scores of health-related quality of life. Qual Life Res 2003;12:11‐20
   PubMed Web of Science ®Google Scholar
• Szende A, Brazier J, Schaefer C, et al. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. Curr Med Res Opin 2010;26:1893‐903
   PubMed Web of Science ®Google Scholar
• Hahn E, Cella D. Health outcomes assessment in vulnerable populations: measurement challenges and recommendations. Arch Phys Med Rehabil 2003;84(4 Suppl):S35‐S42
   PubMed Web of Science ®Google Scholar
• Greenwood M, Hakim A, Carson E, et al. Touch-screen computer systems in the rheumatology clinic offer a reliable and user-friendly means of collecting quality-of-life and outcome data from patients with rheumatoid arthritis. Rheumatology 2006;45:66‐71
   PubMed Web of Science ®Google Scholar
• Lofland J, Schaffer M, Goldfarb N. Evaluating health-relatged quality of life: cost comparison of computerized touch-screen technology and traditional paper systems. Pharmacotherapy 2000;20:1390‐5
   PubMed Web of Science ®Google Scholar
• Crawley J, Kleinman L, Dominitz J. User preferences for computer administration of quality of life instruments. Drug Info J 2000;34:137‐44
   Web of Science ®Google Scholar